Core Insights - Fangzhou Inc. has appointed Mr. Wang Haijiao as the new CEO, effective March 26, 2026, succeeding former CEO Mr. Xie Fangmin [1][2] - The company reported a significant financial turnaround for fiscal year 2025, achieving a net profit of RMB12.0 million and a 30.2% year-over-year revenue increase to RMB3.53 billion [2] - Mr. Wang brings nearly 20 years of experience in the healthcare industry, with expertise in digital health and precision medicine, previously holding key positions at GTJA Investment Group and Dragon Rise Capital [3] Company Strategy and Vision - Mr. Wang emphasized the importance of leveraging Fangzhou's digital healthcare infrastructure and proprietary XS LLM to enhance care standards for millions of patients and support over 250,000 physicians [4][5] - The company aims to deepen its 'AI + CDM' strategy and continue executing its 'Medicine as a Service' (MaaS) model under Mr. Wang's leadership [4] - Fangzhou's recent initiatives include the launch of the multimodal "XingShi" Large Language Model (XS LLM) to improve user experience and diagnostic accuracy [5] Company Profile - Fangzhou Inc. is recognized as China's leading online chronic disease management platform, serving 56.4 million registered users and 251,000 physicians as of December 31, 2025 [6] - The company specializes in providing tailored medical care and AI-enabled precision medicine solutions [6]